



Press release

## End of the conversion of convertible bonds issued in 2018

Dijon, 12 April 2019

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations, announces the end of the conversion of convertible bonds issued in 2018.**

Bond debt, which amounted to €5.5 million at the end of 2018, accordingly amounted to €0.1 million at the end of March 2019. Successive conversions in the first quarter of 2019 helped increase equity by €5.4 million. Based on the situation as of 31 December 2018, this brought shareholders' equity to €7.1 million.

For the record, Crossject issued two convertible bonds in 2018. The first issue of €5.25 million in February 2018 was due to mature on 11 February 2020. The second €2.5 million issue was completed in July 2018, with a two-year maturity. The conversion of these bonds before their maturity illustrates the bondholders' confidence in Crossject's development potential.



## Contacts:

Crossject  
Patrick Alexandre  
[info@crossject.com](mailto:info@crossject.com)

Investor relations  
CM-CIC Market Solutions  
Catherine Couanau +33 (0)1 53 48 81 97  
[catherine.couanau@cmcic.fr](mailto:catherine.couanau@cmcic.fr)

Press relations  
Buzz & Compagnie  
Mélanie Voisard +33 (0)3 80 43 54 89  
[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)  
Audrey Lachat +33 (0)3 80 43 54 89  
[audrey.lachat@buzzetcompagnie.com](mailto:audrey.lachat@buzzetcompagnie.com)

## About CROSSJECT · [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, severe migraine, allergic shock, overdose and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and has received financing from Bpifrance.